Promontory Therapeutics
Ejecutivos
Ver el organigrama con sus 16 ejecutivos principales
Biografías más buscadas en Promontory Therapeutics
- Robert Fallon, Chairman, President and Chief Executive Officer
- Charles Stuckey, Director
- Neil Sunderland, Director
Crear su alerta
para seguir los movimientos de los ejecutivos en Promontory Therapeutics.
Biotecnología
Promontory Therapeutics tiene 2.284 competidores entre los que se incluyen Lonza (Suiza), Eurofins (Luxemburgo) y Adaptive Phage Therapeutics (Estados Unidos).
Popular M&A news in Biotecnología
- Transcarent acaba de anunciar una recaudación de fondos de 126 millones de dólares. (publicado el 2 de mayo de 2024).
- WindRose Health Investors has announced the acquisition of SubjectWell (publicado el 2 de mayo de 2024).
- Enlaza Therapeutics acaba de anunciar una recaudación de fondos de 100 millones de dólares. (publicado el 2 de mayo de 2024).
Otros contactos sugeridos en el sector Biotecnología
Noticias
Últimos comunicados de prensa de Promontory Therapeutics
- Promontory Therapeutics Completes Enrollment of Phase 2 Trial of PT-112 in Late-Line Patients with Metastatic Castration-Resistant Prostate Cancer | Promontory Therapeutics | Advancing small molecule immunotherapy
- Press Releases | Promontory Therapeutics | Advancing small molecule immunotherapy
- Press Releases | Promontory Therapeutics | Advancing small molecule immunotherapy
- Promontory Therapeutics Presents Data on Molecular Mechanisms of PT-112's Immunogenic Effects | Promontory Therapeutics | Advancing small molecule immunotherapy
- The Galien Foundation Announces 2023 Prix Galien USA Nominees for "Best Digital Health Solution," "Best Medical Technology," "Incubators, Accelerators and Equity," and "Best Startup" | Promontory Therapeutics | Advancing small molecule immunotherapy
- Promontory Therapeutics to Present Data on PT-112 Mechanism of Action at the Society for Immunotherapy of Cancer's 38th Annual Meeting | Promontory Therapeutics | Advancing small molecule immunotherapy
- Press Releases | Promontory Therapeutics | Advancing small molecule immunotherapy
- Press Releases | Promontory Therapeutics | Advancing small molecule immunotherapy
- Promontory Therapeutics Presents Data on the Molecular Effects of PT-112 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics | Promontory Therapeutics | Advancing small molecule immunotherapy
- Promontory Therapeutics Announces Early Phase 2 Clinical Trial Data From the National Cancer Institute, Demonstrating PT-112's Immune Activation in Thymic Epithelial Tumors | Promontory Therapeutics | Advancing small molecule immunotherapy
- View more press releases Close
Redes sociales sobre Promontory Therapeutics
- Promontory Therapeutics en Wikipedia, Google News y Yahoo Finance
- Promontory Therapeutics en LinkedIn, Twitter y YouTube
Ponerse en contacto
Contactar a través de e-mail con sus ejecutivos Peter Espig 
Llame a Promontory Therapeutics al +1 646...
